Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%
- Check17 days agoChange Detected- Version indicator updated from v3.0.2 to v3.1.0, signaling a new release.SummaryDifference0.1%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has added a facility name, location, and the MVAp53 vaccine, while removing extensive information related to ovarian cancer and various medical topics, including the pembrolizumab drug.SummaryDifference3%
- Check60 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.